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A mixed methods case study investigating
how randomised controlled trials (RCTs) are
reported, understood and interpreted in
practice
Ben E. Byrne1* , Leila Rooshenas1, Helen S. Lambert2 and Jane M. Blazeby1,3,4
Abstract
Background: While randomised controlled trials (RCTs) provide high-quality evidence to guide practice, much
routine care is not based upon available RCTs. This disconnect between evidence and practice is not sufficiently
well understood. This case study explores this relationship using a novel approach. Better understanding may
improve trial design, conduct, reporting and implementation, helping patients benefit from the best available
evidence.
Methods: We employed a case-study approach, comprising mixed methods to examine the case of interest: the
primary outcome paper of a surgical RCT (the TIME trial). Letters and editorials citing the TIME trial’s primary report
underwent qualitative thematic analysis, and the RCT was critically appraised using validated tools. These analyses
were compared to provide insight into how the TIME trial findings were interpreted and appraised by the clinical
community.
Results: 23 letters and editorials were studied. Most authorship included at least one academic (20/23) and one
surgeon (21/23). Authors identified wide-ranging issues including confounding variables or outcome selection. Clear
descriptions of bias or generalisability were lacking. Structured appraisal identified risks of bias. Non-RCT evidence
was less critically appraised. Authors reached varying conclusions about the trial without consistent justification.
Authors discussed aspects of internal and external validity covered by appraisal tools but did not use these
methodological terms in their articles.
Conclusions: This novel method for examining interpretation of an RCT in the clinical community showed that
published responses identified limited issues with trial design. Responses did not provide coherent rationales for
accepting (or not) trial results. Findings may suggest that authors lacked skills in appraisal of RCT design and
conduct. Multiple case studies with cross-case analysis of other trials are needed.
Keywords: Randomised controlled trial, surgery, Methods, Translational medical research, Health services research,
Evidence-based medicine
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Background
It is widely recognised that clinical practice is often not
in line with the best available evidence. This is the so-
called ‘gap’ between research and practice [1, 2]. Best
evidence predominantly comes from well designed and
conducted randomised controlled trials (RCTs) [3].
However, RCTs are often complex and challenging. Sur-
gical RCTs present specific issues with recruitment,
blinding of patients and surgeons, and intervention
standardisation [4]. Many of these issues have been clari-
fied with methodological research [5–10]. Such work has
led to improvements in trial quality over time [11, 12].
However, the gap between trials and implementation of
their results in practice persists [13], potentially com-
promising patient care and wasting resources. Reasons
for the disconnect are myriad.
Trial findings that report putative evidence for a
change in clinical practice may not be implemented be-
cause of poor conduct and reporting [14], limitations in
generalisation and applicability [15], cost, and unaccept-
ability of new interventions. Clinical culture may empha-
sise the importance of experience over evidence [16],
and some clinicians may have limited numeracy skills re-
quired to understand and apply quantitative results from
trials [17]. Appropriate understanding of RCTs is critical
to implementation and of vital importance to clinicians,
researchers and funders. We have previously described a
novel approach to explore understanding and interpret-
ation of RCT evidence, by examining writings about in-
dividual surgical trials [18]. The present study aims to
apply this new method to a single case study: the TIME
(Traditional Invasive versus Minimally invasive Esopha-
gectomy) RCT [19]. The purpose is to better understand
how this trial has been interpreted and to illustrate the
potential of this novel approach.
Methods
The methodology used in this study has been described
in detail elsewhere [18] and will be summarised here.
The approach represents a form of case-study research,
comprising mixed methods analysis of documentary evi-
dence relating to a published RCT [20]. Case-study ap-
proaches have been defined in various ways and used
across numerous disciplines. Their central tenet is to ex-
plore an event or phenomenon in depth and in its nat-
ural context [21]. The ‘real-world context’ in this study
was the landscape of published articles that interpreted,
appraised and discussed implementation of the TIME
trial’s findings. Our approach aligned with Stake’s ‘in-
strumental case-study’ [22], using a particular case (the
TIME RCT’s outcomes paper) to gain a broader appreci-
ation of the issue or phenomenon of interest (in this
case, interpretation and appraisal of RCTs in the clinical
community, and implications for implementation). We
conducted qualitative analysis of selected published arti-
cles citing this RCT’s primary report and compared this
with structured critical appraisal of the RCT using estab-
lished tools. We also sought to demonstrate the utility of
this novel approach, which we intend to apply in future
case studies.
Identify and analyse articles citing a trial
Purposefully select a major surgical RCT
An index RCT was identified and summarised as the
case of interest. We sought a highly cited trial report,
published in a high-impact journal within the last 10
years. The TIME trial [19], comparing open and minim-
ally invasive surgical access for removal of oesophageal
cancer, was selected as it met these criteria and was
within our area of expertise.
Identify and systematically sample articles citing the RCT
All articles citing this RCT were identified using Web of
Science and Scopus citation tracking tools. Letter, edi-
torial and discussion article types were included. On-line
comments were identified using the Altmetric.com
bookmarklet. Non-English language articles were ex-
cluded. Searches were conducted in October 2017.
Undertake in-depth qualitative analysis and identify
relevant themes
Included articles were thematically analysed using the
constant comparison technique, adopted from grounded
theory [23, 24]. Articles were read in detail, with no a
priori coding framework. Text was considered against
the research topic, which focused on understanding how
the authors interpreted, appraised and/or applied the
findings of the trial. New findings or interpretations
were continuously related to existing findings to develop
the data set as a whole (i.e. the constant comparison
technique). Coding was not constrained by pre-defined
boundaries defining relevance. Rather, this was guided
by the content of the articles being analysed. During
analysis, it transpired that understanding authors’ inter-
pretations of the RCT required examination of their dis-
cussion of evidence from other studies. Therefore, other
articles cited by the authors were sought to determine
the types of evidence being referenced. The designs of
these additional studies were ascertained based on the
descriptions in those articles (rather than our
assessment).
Analysis was performed by BEB and LR. BEB is a se-
nior surgical trainee and postdoctoral researcher with
previous experience of qualitative research. LR is a Lec-
turer in Qualitative Health Science with an interest in
trial recruitment issues, implementation of trial evi-
dence, and experience of working on multiple surgical
RCTs. Both researchers work within a department with
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expertise in trials methodology and have detailed know-
ledge in this field which is likely to have influenced their
identification and coding of relevant themes.
Two rounds of double coding of five articles were per-
formed by BEB and LR. Further coding was conducted
by BEB and reviewed among the team to revise coded
themes. Descriptive data on authorship and origins of
the articles were collected.
Summarise validity and reporting of the RCT
The RCT was assessed by BEB using a range of critical
appraisal tools commonly used to appraise RCTs. These
included two of the most commonly used tools to assess
RCTs: one examining trial reporting in a broad sense
(Consolidated Standards of Reporting Trials for Non-
Pharmacological Treatments (CONSORT-NPT) [5]),
and another focusing on internal validity as commonly
assessed in systematic reviews of trials (the updated
Cochrane Risk of Bias Tool (ROBT 2.0) [7]). In addition,
the Pragmatic Explanatory Continuum Indicator Scale
(PRECIS-2) tool [8] was included, to examine domains
associated with the broad applicability and utility of the
trial, and the Context and Implementation of Complex
Interventions (CICI) framework [25] was included on an
exploratory basis to identify broader contextual factors
that could be relevant. JMB contributed to assessment
during piloting of the tools and in discussion with BEB
where there was uncertainty.
Broad comparison of all results to develop deeper
understanding of how trials are understood and
relationship with trial quality
The results of both qualitative analysis and structured
critical appraisal were considered side-by-side, with the
overall aim of better understanding how other authors’
interpretations of the TIME trial compared with the crit-
ical appraisal guided by the above tools. The qualitative
analysis of the authors’ interpretations was conducted
before the structured critical appraisal to ensure the cod-
ing/themes were grounded in authors’ writings, rather
than our experience of conducting the structured ap-
praisals. The final step aimed to draw together both ana-
lyses, to see whether authors discussing the trial raised
concerns across similar domains to the areas covered by
the critical appraisal tools, or whether their topics of dis-
cussion addressed other considerations.
Ethical considerations
This study involved secondary use of publicly available
written material and did not require ethical review.
Patient and public involvement
Patients and members of the public were not involved in
any aspect of the design of this study.
Results
Summary of index RCT
The TIME trial was a two-group, multicentre rando-
mised trial comparing a minimally invasive approach
to the surgical removal of oesophageal cancer with an
open approach to the abdomen and chest. It was con-
ducted in five centres across four European countries
from 2009 to 2011 and is summarised in Table 1.
Characteristics of articles
Searches identified 26 articles, and 23 were included
(exclusions: an incorrectly classified case report and
two articles in German). Summary characteristics are
provided in Table 2. Most articles (18/23, 78%) origi-
nated from Europe or the United States. The majority
(20/23, 87%) included at least one author holding an
academic position; 18/23 (78%) included at least one
professor or associate professor (as defined within
their own institution). Nearly all included at least one
consultant or trainee surgeon (21/23, 91%).
Altmetric.com identified several references to the
TIME trial, detailed in Table 3. Only one, part of the
British Medical Journal blog series, included text dis-
cussing the trial, rather than simply restating its results
or directing readers to the study report.
Themes identified
Qualitative analysis resulted in description of three
key themes: identification of wide-ranging issues
with the RCT; limited appraisal of non-RCT studies;
and variable recommendations for future practice
and research. Codes linking quotes to articles and
bibliographic data are provided in supplementary
Table 1.
Identification of wide-ranging issues with the RCT
Authors extensively discussed and critiqued several fea-
tures of trial design and conduct. These included the
population, intervention and outcomes of the trial.
If the author’s primary outcome was focused on pul-
monary infection, perhaps other patient associated
inclusion / exclusion criteria may have been of
value. These would include patients with poor pul-
monary function parameters … patients with major
organ disease … and recent history of prior malig-
nancy. (E2).
In the present [TIME] trial, the difference between
minimally invasive and open oesophagectomy was
maximised with a purely thoracoscopic (prone pos-
ition) and laparoscopic technique. (E1).
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Table 1 Summary of TIME trial
Domain Description
Population • Patients with surgically resectable (cT1–3, N0–1, M0) squamous cell carcinoma, adenocarcinoma or undifferentiated carcinoma of the
intrathoracic oesophagus or Siewert type 1 oesophago-gastric junction tumours
• Underwent neoadjuvant therapy
• Age ≥ 18 years and≤ 75 years
• European Clinical Oncology Group performance status 0–2
Intervention • Minimally Invasive Oesophagectomy (MIO): supine laparoscopic gastric mobilisation and prone thoracoscopic procedure with either
cervical or intra-thoracic anastomosis
Comparator • Open two- or three-phase oesophagectomy with cervical or intra-thoracic anastomosis
Outcome • 2-week and in-hospital pulmonary infection rates
Results • 59 patients had MIO and 56 patients underwent open surgery
• 9% vs 34% pulmonary infection rate (relative risk 0.30, 95% confidence interval 0.12–0.76, p = 0.005)
Conclusion • This ‘first randomised trial’ comparing MIO and open approach provided ‘evidence for the short-term benefits of minimally invasive
oesophagectomy for patients with resectable oesophageal cancer’.
Table 2 Summary of characteristics of included articles
n = 23
Article type Editorial / discussion 13
Letter 10








Academic authorship At least one professor / associate professor 18
At least one other academic position 2
No academic authorship 3
Surgeon authorship At least one consultant surgeon 20
At least one trainee surgeon 1
No surgeons 2
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The primary outcome … was pulmonary infection
within the first 2 weeks after surgery and during the
whole stay in hospital. This cannot be considered as
the relevant primary outcome with reference to the
decision problem outline by the authors … (E5).
Beyond these basic trial design parameters, authors of
the citing articles also highlighted important confound-
ing variables.
Many non-studied variables, including malnutrition,
previous and current smoking, pulmonary comorbid-
ities, functional status, and clinical TNM (tumour,
node, metastasis) staging, have all been shown to
strongly affect the primary endpoint of this trial –
postoperative pulmonary infection. (L2).
Several correspondents suggest that lower rates of re-
spiratory infection might have been achieved by use
of alternative strategies for preoperative preparation,
patient positioning, ventilator settings, anaesthetic
agents, or postoperative care. (L6).
The articles also covered other potential problems
with the trial, such as sample size and learning curve
effects.
The sample size for sufficient statistical power for major
morbidity, survival, total morbidity and other similarly
important outcomes may actually be larger. (E2).
The inclusion criteria for participating surgeons ap-
pears to have the performance of a minimum of only
10 MIOs and this low level of experience may be
reflected in relatively high conversion rate of 13%.
(E4).
Only one article (E2) made clear statements praising
aspects of the trial:
‘…The protocols for the RCT appear sound with
randomization, intention to treat, PICO … and bias
elimination.’
The next sentence of this article balanced these posi-
tive comments with discussion of limits due to the lack
of blinding and other potential confounding variables.
Limited appraisal of non-RCT studies
Authors often cited other types of evidence in the same
field to support their views without discussing their
methodological limitations. Types of evidence included
single-surgeon series, non-randomised comparative
studies, systematic reviews (SRs) and meta-analyses
(MAs).
Luketich et al., one of the earlier pioneers of MIE, re-
ported their extensive experience of 1033 consecutive
patients undergoing MIE with acceptable lymph
node resection, postoperative outcomes, and a 1.7%
mortality rate. (L8).
In a population-based national study, … the inci-
dence of pneumonia was 18.6% after open oesopha-
gectomy and 19.9% after minimally invasive
oesophagectomy … (L3).
Although systematic reviews and a large compara-
tive study of minimally invasive oesophagectomy
have not shown this technique to be beneficial as
compared with open oesophagectomy, some meta-
analyses have suggested specific advantages. (E1).
The existing SRs and MAs were discussed in relation
to the intervention and its outcomes, without directly re-
lating them to the TIME trial itself. The implications for
authors’ impressions of the TIME trial findings were
generally unclear.
There was limited appraisal of these SRs and MAs, es-
pecially when contrasted with discussion of the TIME
Table 3 Summary of references to TIME trial identified using Altmetric.com (searched 10 September 2018)
Type Description n
Blog One part of a journal review on a British Medical Journal blog page, summarising problems with TIME trial in one
sentence.
1
Policy document National Institute for Health and Care Excellence National Guideline 83 on assessment and management of oesophago-
gastric cancer. National policy document including evidence synthesis of trial results with no specific discussion of TIME
trial.
1
Tweets No discussion of TIME trial. 11 retweets from The Lancet, several others based on same tweet. 24





3 members of F1000Prime recommended this trial. 1
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trial. Several authors referred to the large, single-surgeon
series of MIO by Luketich, but only one author de-
scribed limits of this single-institution non-comparative
study.
We must not rely on the limitation of single-
institution studies and historical data. This proced-
ure must be broadly applicable and not the domain
of a few experts for it to become the new gold stand-
ard. (E12).
A few others highlighted the limits of other study de-
signs, but there was a striking disparity in the level of
critique, when compared with that of the TIME trial.
In their systematic review … Uttley et al. correctly
conclude that due to factors such as selection bias,
sufficient evidence does not exist to suggest the MIO
is either equivalent to or superior to open surgery.
(E6).
All these studies however, concede that due to a lack
of feasible evidence by way of prospective random-
ized controlled trials (RCT), no definitive statement
of MIE ‘superiority’ over standard open techniques
can be made. (E2).
Although several authors referred to the existing SRs
and MAs, none reported the design of the included pri-
mary studies, which were largely retrospective and non-
randomised.
Variable recommendations for future practice and research
The authors had differing interpretations and recom-
mendations for implementation based on the TIME trial.
Some articles discussed issues with the trial and did not
make recommendations for future practice, in some
cases asking for additional information to better under-
stand or interpret the trial.(L1, L3–5) For example, one
simply wrote that the authors ‘have several concerns’,
before reporting differences in outcomes between TIME
and other studies, and describing practice in their own
institution. (L1) Others reported that more work was re-
quired, such as further analysis of long-term results of
patients included in TIME, or called for further trials in
different patient populations.
However, the main issue which this study [TIME]
does not address is that of long-term survival. … If
the authors can indeed demonstrate at least equiva-
lent long-term oncological outcome for MIO and
open oesophagectomy, then this paper should provide
an impetus for driving forward the widespread adop-
tion of MIO. (E4).
Of interest will be whether similar results can be re-
peated in patients in Asia, with mainly squamous
cell cancers that are proximally located. … The sub-
stantial benefit shown in this trial [TIME] … might
encourage investigators to do further randomised
studies at other centres. If these results can be con-
firmed in other settings, minimally invasive oesopha-
gectomy could truly become the standard of care.
(E1).
One article (E6) considered the evidence for MIO, dis-
cussed this against methodological aspects of a colorec-
tal trial evaluating a minimally invasive approach, before
restating the findings of TIME, opining that:
‘This study confirms that RCT [sic] for open versus
MIO is indeed possible, but further larger trials are
required.’
Later in that article, the authors suggested extensive
control of wide-ranging aspects of perioperative care
would be important for future trials.
Authors of three articles (E7, E9, E11) suggested that
the available evidence was enough for increasing adop-
tion of MIO.
…The available evidence increasingly favors a prom-
inent role for minimally invasive approaches in the
management of esophageal cancer. Endoscopic ther-
apies and minimally invasive approaches offer at
least equivalent oncologic outcomes, with reduced
complications and improved quality of life compared
with maximal surgery. (E11).
We are close to a situation in which one can argue
that MIE is ready for prime time in the curative
treatment of invasive esophageal cancer. If we critic-
ally analyse the level and grading of evidence, the
current situation concerning MIE and hybrid MIE is
far better than was the case when laparoscopic
cholecystectomy, anti-reflux surgery, and bariatric
surgery were introduced into clinical practice. (E9).
No authors called for the cessation of MIO, although
one referred to some centres stopping ‘their MIE [min-
imally invasive esophagectomy] program due to safety
reasons’. (E13).
Assessment of RCT using validated tools
The TIME trial results and protocol papers [19, 26] were
examined to assess the trial and its reporting.
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Assessment using CONSORT-NPT demonstrated
reporting shortfalls in several areas (full notes in supple-
mentary Table 2). These included: lack of information
on adherence of care providers and patients to the treat-
ment protocol; discrepancies between the primary out-
comes proposed in the protocol (3 pulmonary
outcomes) and the trial report (one pulmonary result);
no information on interim analyses or stopping criteria;
a lack of information regarding statistical analysis to
allow for clustering of patients by centre; and absence of
discussion of the trial limitations or generalisability.
Risk of bias was assessed as shown in Table 4. Overall,
the TIME trial was considered at high risk of bias.
Assessment using the PRECIS-2 tool is shown in
Table 5. Overall, TIME had features in keeping with a
more pragmatic rather than explanatory trial. This sug-
gested a reasonable degree of applicability and usefulness
to wider clinical practice.
Application of the CICI framework highlighted several
higher-level considerations relevant to the applicability
of the TIME trial not described in the protocol or study
report (see Table 6). These included lack of detail on the
setting, as well as epidemiological and socio-economic
information.
Overall, these tools suggested that TIME had several
limitations. These included issues with standardisation
and monitoring of intervention adherence, lack of blind-
ing, failure to use hierarchical analysis and a lack of in-
formation on provider volume. The risk of bias was
high, limiting confidence attributing outcomes to the al-
located interventions. Broad applicability was considered
reasonable, though study utility was compromised by a
short-term clinical outcome, rather than longer term or
patient-reported outcomes. While TIME may have pro-
vided early evidence for benefit of MIO to reduce pul-
monary infection within 2 weeks of surgery, the
appraisal suggested more evidence was needed before
considering wider adoption of MIO.
Broad comparison of all results to develop deeper
understanding
We considered the findings from the qualitative analysis
in relation to those of the critical appraisal. In doing so,
broad domains of internal and external validity seemed a
useful system to bring together results of both analyses.
While the ROBT was described by its creators as fo-
cused on internal validity, the PRECIS-2 and CICI tools
were not described in terms of validity. Rather, their au-
thors referred to applicability and reproducibility in
other settings, which may also be described as external
validity. CONSORT-NPT is a tool focused on reporting
of trials, and its authors referred to both domains, with
some duplication of factors covered in the other tools.
However, authors of the articles included in the qualita-
tive analysis did not adopt such methodological termin-
ology when expressing concerns about these aspects of
the index RCT’s conduct or reporting.
Robust internal validity allows confident attribution of
treatment effects to the experimental intervention. The
ROBT identified high risk of bias in the TIME trial.
Qualitative analysis revealed discussion of various as-
pects relevant to internal validity. For example, several
Table 4 Risk of bias determined using the Cochrane Risk of Bias Tool 2.0
Domain of bias Bias
judgement
Support for judgement
Randomisation Low ‘When informed consent is obtained, the patient will be randomized at the outpatient clinic.
Randomization is performed per center by an internet randomization module maintained by
coordinators at the VUmc.’
Deviations from intended
interventions
High ‘Patients, and investigators undertaking interventions, assessing outcomes, and analysing data were not
masked to group assignment.’
‘Open oesophagectomy involved … the lateral decubitus position with double tracheal intubation and
lung block… Minimally invasive oesophagectomy was performed … in the prone position … with
single-lumen tracheal intubation…’
Missing outcome data Low All randomised patients included in intention-to-treat analysis.
Measurement of outcome High ‘Patients, and investigators undertaking interventions, assessing outcomes, and analysing data were not
masked to group assignment.’
Imaging and sputum culture decisions made by team providing postoperative care for patient, not
blinded to treatment allocation.
Selection of reported result High Protocol: ‘The primary endpoint of this study concerns the respiratory complications (i.e. infections)
within two weeks after the operation. This is categorized as: grade 1) initial respiratory after operation
with continued mechanical ventilation; grade 2) after successful detubation, clinical manifestation of
respiratory infection caused by (broncho) pneumonia, confirmed by thorax X-ray or CT scan … and a
positive sputum culture; and grade 3) other thoracic infections…’
Report: the primary outcome was postoperative pulmonary infection, defined as clinical manifestation of
pneumonia or bronchopneumonia confirmed by thoracic radiographs or CT scan … and a positive
sputum culture …’
Overall High
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authors discussed differences in patient positioning and
anaesthetic techniques. These confounding variables
may have introduced systematic differences in care be-
tween groups, aside from the allocated intervention,
resulting in bias. However, the article authors did not ar-
ticulate the implications of their concerns in such terms
and did not consider whether these problems rendered
the trial fatally biased.
Sound external validity suggests similar treatment
effects may be achieved by other clinicians in other
settings for other patients. Pragmatic trials have
broad applicability, with wide inclusion criteria, and
patient-centred outcomes. The PRECIS-2 describes
domains relevant to this applicability. TIME had sev-
eral features of a pragmatic trial, suggesting rela-
tively broad applicability. The qualitative analysis
showed authors were concerned about these issues.
For example, several discussed the appropriateness
and utility of 2-week and in-hospital pulmonary in-
fection rates as the primary outcome measure. How-
ever, authors did not directly relate such concerns to
external validity or generalisability, to reach a con-
clusion about whether the trial should influence
practice.
Table 5 Assessment of the TIME trial using the PRECIS-2 tool
Domain Rating Support for judgement
Eligibility criteria 3 Included oesophageal and Siewert 1 tumours; pre-operative T1–3, N0–1; aged 18–75 years. Therefore, excluded Siewert 2,
pre-operative T4 and N2–3, those aged > 75 years.
Recruitment path 5 ‘The patient will be informed about the trial at the outpatient clinic.’
Setting 4 International study across 5 centres in 3 countries in Europe, including academic and non-academic units. Units performing
> 20 oesophagectomies per year.
Organisation 3 No extra staffing. Surgeons in some centres had been proctored by lead centre, but not as part of the trial. Surgeons from
these centres submitted videos to judge their experience and skill to be allowed to participate. Other centres ‘already well
experienced’. Surgeons required a minimum of 10 MIO to participate.
Flex of experimental intervention
- delivery
3 Operation was specified in protocol, but not exhaustively. For either open or MIO, the operation could be 2 or 3 stage. There
was no monitoring to ensure compliance. Positioning and aspects of anaesthesia were specified, including left decubitus
position and right lung block for open thoracotomy, with prone positioning and no lung block for MIO.
Flex of experimental intervention
- adherence
– As per PRECIS-2 toolkit, not applicable when patients undergoing surgery.
Follow-up 5 Follow-up as per usual practice, at 6 weeks, 3 months, 6 months and 1 year, until 5 years postop.
Outcome 3 Primary outcome outlined in the protocol included all pulmonary infections, with 3 categories discussed. However, the trial
report only presents one of these 3 categories, pneumonia (CXR/CT changes and positive sputum culture). No patient-
centred outcomes, such as Patient Reported Outcome Measures. Outcomes were measured early in the patient’s recovery
from the procedure.
Analysis 5 Intention-to-treat analysis of all randomised patients with no apparent loss to follow-up.
Median 3.5
Table 6 Notes on domains relevant to the implementation of MIO based upon the CICI checklist
Domain Notes
Setting Report describes types of hospital, total number of centres and countries participating in the study.
Geographical Participating countries identified, but no discussion of access to healthcare system in each.
Epidemiological No discussion of incidence and prevalence of the condition, usual morbidity and mortality rates.
Socio-economic No discussion of burden of disease or access to the healthcare system.
Socio-cultural Uncertain relevance of this domain for this study, intervention and the intended audience for the trial.
Political No discussion of the type of healthcare system, its resources and access.
Legal No discussion of guidelines outlining the existing role of the intervention.
Ethical Statement declaring no conflict of interests included.
Provider Details of the skills, experience and training of participating surgeons was included. No discussion of attitudes towards the
intervention or motivation for participating in the trial.
Organisation and
structure
No discussion of the size, structure and culture of the participating organisations. However, as a multicentre study, natural
variation in these variables will have occurred, improving external validity.
Finance Funding for the trial was acknowledged. However, there was no discussion of financial incentives, costs or future funding for
adoption of the intervention.
Policy No discussion of the role of evidence-based medicine in determining policy.
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While many authors identified issues relevant to in-
ternal and external validity, the lack of clear explanation
of their implications meant it was difficult to determine
whether they thought the trial justified a change in prac-
tice. This contrasts with the structured assessments,
which defined clear problems with the trial and limits to
its usefulness.
Discussion
This study presents the first application and results of a
new method to generate insights into how evidence from
a trial was understood, contextualised and related to
practice. Qualitative analysis of letters and editorials,
largely written by academic surgeons, documented ex-
tensive discussion of problems with the trial, but without
clear formulation of the implications of these concerns
for its internal or external validity and applicability.
These authors reached a variety of conclusions about
the implications of the trial for surgical practice. A sep-
arate assessment using structured tools defined specific
weaknesses in trial methodology. Whilst this new ap-
proach yielded useful findings in this single case study,
the method should be further tested using multiple trials
and cross-case analyses. The initial findings based on
this single case study suggest a need to clarify standards
against which a trial may be assessed to guide decisions
about its role in changing practice, and potentially also
to guide efforts to influence practitioners to implement
change if appropriate. Within this, our findings suggest a
need to focus efforts on educating surgeons about trial
design and quality, which may contribute to implemen-
tation science-based efforts to inform clinical decision-
making and implementation of trial results.
This study contributes to the wider literature showing
that evidence does not speak for itself. New evidence is
often considered alongside competing bodies of existing
evidence that may support different ideas, theories or in-
terventions [27, 28]. When a study is published, this new
evidence is assimilated into the wider scientific context.
Its strengths, weaknesses and overall contribution are
debated and disputed. Through the lens of Latour’s
actor-network theory [29, 30], the new trial can be con-
sidered a novel actor within the wider network of actors
that includes other trials and studies of the intervention,
as well as the consumers of this evidence. Those com-
menting on the trial have an important role in how dif-
ferent features of the trial are identified, discussed and
debated, and how its findings are framed. This agency
may be influenced by their own clinical experience, edu-
cation, skill set, work environment and colleagues,
amongst other factors. Given these complexities, it is not
surprising to find that different authors reached different
conclusions about the TIME trial.
The way authors of the included articles used and ap-
praised different types of study raises questions about
how the hierarchy of evidence, and the primacy of the
RCT, is applied to routine clinical practice. We found
extensive criticism of the TIME trial. Article authors de-
scribed several limitations relating to its population,
intervention, associated co-interventions and confound-
ing variables, as well as the outcomes selected. Certainly,
the authors presented valid criticisms that limited the
trial’s validity, as identified by structured critical ap-
praisal. Over recent years, trials methodologists have
worked to better understand and optimise many such
aspects of trial conduct. The development of the CON-
SORT reporting standards promotes detailed description
of key methods, such as random sequence generation
and allocation concealment, that allow critical judge-
ments about internal validity to be made [5]. The growth
of pragmatic trials, featuring wide inclusion criteria, con-
ducted across multiple sites, with clinically meaningful
outcomes, reflects a concerted effort to improve applic-
ability or external validity of RCTs [8, 31]. It may never
be possible to conduct a ‘perfect’ trial, but improvements
in the rigor and transparency of design hopefully ensure
that RCTs can provide sufficiently robust evidence that
is useful to the broad population of patients and clini-
cians within a healthcare system. Whether these devel-
opments, designed to address valid criticisms of RCTs,
are widely understood outside the sphere of trials meth-
odologists is unclear.
Conversely, the authors of the included articles were
far less critical of non-RCT evidence. For example, sev-
eral authors referred to the single-surgeon case-series of
Luketich [32]. Only one author discussed its limitations
for generalisation. Surgical skill and performance vary
[33]; what is possible for a single surgeon cannot be gen-
eralised to what is usual for most. Similarly, authors
cited systematic reviews and meta-analyses without clear
description of the original study designs. Evidence syn-
thesis cannot eliminate biases in retrospective, non-
randomised studies using statistical techniques. Failure
to clearly articulate limitations of these different studies
may support our contention that the authors lacked ap-
propriate appraisal skills. Alternatively, it may suggest
bias in favour of the intervention, such that the authors
understood, but did not want to articulate its limitations.
While RCTs have not been toppled from their position
at the top of the hierarchy of evidence about the efficacy
of interventions, developments in other areas have seen
increasingly sophisticated use of observational data to
better understand the effects of treatments. Researchers
have taken advantage of increasing availability of vast
quantities of genetic data. In epidemiology, the concept
of Mendelian randomisation has been used to try and
unpick causal relationships from non-causative
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correlations [34]. At the patient level, genetic testing of
different types of cancer has allowed targeting of treat-
ments according to cellular sensitivities [35]. The devel-
opment of such markers by which to tailor treatment
have led to proposals of an idealised future whereby in-
dividual treatments are entirely personalised according
to a panel of markers that accurately predict treatment
response and prognosis. These different research ap-
proaches are inevitably competing for resources and in-
tellectual priority. However, as has been argued by
Backmann, for these other study types to take priority,
“what needs to be shown is not only that RCTs might be
problematic …, but that other methods such as cohort
studies actually have better external validity.” [36]
Evidence-based medicine aims to apply the best avail-
able evidence to individual patients [37]. This aim, by its
very nature, creates a disconnect between evidence from
RCTs, which are aggregated studies of groups of patients
to determine average effects, and clinical decision-
making at the individual level [38]. This could be consid-
ered to represent an insurmountable ‘get-out’ clause,
whereby a clinician may always justify deviation from
‘the evidence’ due to differences between the patient in
front of them and those included in the relevant study.
It may also prove very difficult to allow the theory-based
weight of a journal article to over-ride an individual cli-
nician’s personal lived experience of different interven-
tions and their efficacy. This may be particularly
problematic in surgical practice [16] where the practi-
tioner is usually physically connected with the interven-
tion. This may increase the importance attached to
experience, even if that experience is at odds with large-
scale studies. We do not disagree that clinicians must
treat individual patients according to their specific con-
dition and their wishes. However, it may be considered
that aggregate practice, across a surgeon’s cases or
across a department, should fall roughly in line with an
appropriate body of suitably valid and relevant evidence.
Implementation science research has illuminated many
factors affecting implementation beyond knowledge of
the evidence. Damschroder et al. described the Consoli-
dated Framework for Implementation Research (CFIR)
to identify real-world constructs influencing implemen-
tation, relating to the intervention, individuals, organisa-
tions and systems [39]. These included ‘evidence
strength and quality’ as well as ‘knowledge and beliefs
about the intervention’, constructs readily identified
within the present study. Their framework also high-
lights many other important factors such as cost, patient
needs and resources, peer pressure, external policies and
incentives, and organisational culture. Surgical research
has demonstrated wide variation in practice, even in the
presence of high quality evidence [40], and the broad
range of factors affecting implementation of
interventions, such as Enhanced Recovery After Surgery
[41]. Our approach may contribute as another tool to
understand barriers and facilitators to evidence imple-
mentation. It may prove particularly useful in conjunc-
tion with other methods such as interviews and
observations, informed by a relevant framework, such as
the Theoretical Domains Framework [42, 43].
The early promise of our new method needs further
work to conduct multiple case studies of different RCTs
to allow cross-case analyses and a more thorough under-
standing of how RCTs are interpreted and appraised in
the landscape of written commentaries. Examination of
further case-studies may also inform refinements to the
methods. For example, further analyses may indicate re-
curring themes across case-studies, which may in turn
contribute towards a priori coding criteria and more effi-
cient approaches to analyses (e.g. framework analysis
[44]). It will also be important to include assessment of
how each trial is situated in the wider context of relevant
evidence, across study types. For individual trials, com-
bined qualitative and structured analyses may determine
the extent to which that RCT is flawed and requires fur-
ther evaluation in a more methodologically sound study.
Alternatively, it may demonstrate that the problem in
bridging the gap between evidence and practice resides
in the competition between different bodies of evidence,
comprised of different types of study, and appropriate
understanding of their strengths and weaknesses, as well
as their applicability to practice. Work should also be
undertaken to investigate how contemporary practice
may have changed alongside publication of such articles,
to investigate the relationship between what is written
about the trial, and clinical practice as delivered.
While this study has shown the potential of this new
method, its strengths and limitations must be consid-
ered. Rigorous analysis using robust qualitative methods
and double coding by experienced researchers was
undertaken. The articles examined were written without
knowledge that they would be analysed in this manner,
limiting bias this could introduce. The use of multiple
tools to assess the index RCT created a broad overview
of its strengths and weaknesses. The most important
study limitation was that we did not directly explore au-
thors’ understandings and interpretations, so underlying
understanding of the key issues was inferred, rather than
directly scrutinised. Failure to articulate is not the same
as a lack of understanding. Further, we did not ask au-
thors their motivations to publish their articles, an activ-
ity with its own significance. In addition, this study
attempted to provide insights into the authors under-
standing and interpretation of the trial, and it does not
purport to be an assessment of practice itself, which
would benefit from other approaches to investigation
(e.g. qualitative observations, interviews, quantitative
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procedure rate analyses). This study applied our new
method to a single, surgical RCT. The issues identified
may be particular to that intervention, specialty, or trial
design; further case studies are required to determine
broader relevance.
Conclusions
This study has successfully applied a new method to bet-
ter understand how clinicians and academics understand
evidence from a surgical RCT - the TIME trial. It identi-
fied discussion of many issues with the trial, but the au-
thors who cited the trial did not specifically articulate
the implications of these issues in terms of its internal
and external validity. The authors reached a wide range
of conclusions, ranging from further evaluation of the
intervention, to widespread adoption. Structured ap-
praisal of TIME suggested that the trial was at high risk
of bias with limited generalisability. Further application
of this method to multiple trials will allow cross-case
analyses to determine whether the issues identified are
similar across other trials and yield information to better
understand how this type of evidence is interpreted and
related to practice. This approach may be complemented
by other data, such as in-depth interviews. This may re-
veal genuine flaws in trial design that limit application,
or that other issues such as poor understanding or com-
peting non-clinical factors impede the translation of evi-
dence into practice. We hope that this work may help
existing efforts to close the research-practice gap, and
help ensure that patients receive the best care, based
upon the highest level of evidence.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12874-020-01009-8.
Additional file 1 Table S1. Identifying codes and bibliographic
information on all citing articles included in analysis. Table S2.
CONSORT-NPT checklist with notes on TIME trial.
Abbreviations
RCT: Randomised controlled trial; TIME: Traditional Invasive versus Minimally
invasive Esophagectomy; CONSORT-NPT: CONsolidated Standards Of
Reporting Trials for Non-Pharmacological Treatments; PRECIS: PRagmatic
Explanatory Continuum Indicator Scale; CICI: Context and Implementation of
Complex Interventions; ROBT: Risk Of Bias Tool; MIO: Minimally Invasive
Oesophagectomy; SR: Systematic Review; MA: Meta-Analysis
Acknowledgements
We would like to thank Cath Borwick, Information Specialist at the University
of Bristol for her help developing the literature search strategy, advising on
the available tools and highlighting the full range of resources available for
this study.
Authors’ contributions
BEB and JMB conceived the study. BEB, LR, HL and JMB developed the
protocol and refined the study design. BEB and LR conducted the qualitative
analysis. BEB prepared a preliminary draft manuscript. JMB, LR and HL
extensively revised the manuscript. All authors have approved the final
manuscript.
Funding
B E Byrne is supported by the National Institute for Health Research. Jane
Blazeby is a NIHR Senior Investigator. This work was undertaken with the
support of the MRC ConDuCT-II (Collaboration and innovation for Difficult
and Complex randomised controlled Trials In Invasive procedures) Hub for
Trials Methodology Research (MR/K025643/1) and the NIHR Bristol Biomedical
Research Centre at the University Hospitals Bristol NHS Foundation Trust and
the University of Bristol (BRC-1215-20011) and support from the Royal Col-
lege of Surgeons of England Bristol Surgical Trials Centre. The views
expressed are those of the authors and not necessarily those of the NHS, the
NIHR or the Department of Health. The funders had no role in developing
the protocol.
Availability of data and materials
The dataset upon which this work is based consists of articles already
available within the published literature.





The authors declare that they have no competing interests.
Author details
1Centre for Surgical Research, Population Health Sciences, Bristol Medical
School, University of Bristol, Canynge Hall, 39 Whatley Road, Clifton, Bristol
BS8 2PS, UK. 2Population Health Sciences, Bristol Medical School, University
of Bristol, Bristol, UK. 3MRC ConDuCT-II Hub, Bristol Medical School, University
of Bristol, Bristol, UK. 4NIHR Bristol Biomedical Research Centre, University
Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Received: 26 November 2019 Accepted: 6 May 2020
References
1. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA, et al.
Closing the gap between research and practice: an overview of systematic
reviews of interventions to promote the implementation of research
findings. Br Med J. 1998;317:465–8 Available from: http://www.bmj.com/cgi/
doi/10.1136/bmj.317.7156.465.
2. Grol R, Grimshaw J. From best evidence to best practice: effective
implementation of change in patients’ care. Lancet. 2003;362:1225–30.
3. Oxford Centre for Evidence-Based Medicine. Levels of evidence. 2009 [cited
2018 Sep 25]. Available from: http://www.cebm.net/oxford-centre-evidence-
based-medicine-levels-evidence-march-2009/.
4. Ergina PL, Cook JA, Blazeby JM, Boutron I, Clavien P-A, Reeves BC, et al.
Challenges in evaluating surgical innovation. Lancet. 2009;374:1097–104.
Available from. https://doi.org/10.1016/S0140-6736(09)61086-2.
5. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Methods and
processes of the CONSORT group: example of an extension for trials
assessing nonpharmacologic treatments. Ann Intern Med. 2008;148:295–309.
Available from. https://doi.org/10.7326/0003-4819-148-4-200802190-00008.
6. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al.
The Cochrane Collaboration’s tool for assessing risk of bias in randomised
trials. Br Med J. 2011;343:d5928 Available from: http://www.bmj.com/cgi/
doi/10.1136/bmj.d5928.
7. Higgins JPT, Sterne JAC, Savović J, Page MJ, Hróbjartsson A, Boutron I, et al.
A revised tool for assessing risk of bias in randomized trials. Cochrane
Database Syst Rev. 2016;10:CD201601.
8. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The
PRECIS-2 tool: designing trials that are fit for purpose. Br Med J. 2015;350:
h2147 Available from: http://www.bmj.com/cgi/doi/10.1136/bmj.h2147.
9. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA,
et al. What influences recruitment to randomised controlled trials? A review
of trials funded by two UK funding agencies. Trials. 2006;7:1–8.
Byrne et al. BMC Medical Research Methodology          (2020) 20:112 Page 11 of 12
10. Donovan JL, Rooshenas L, Jepson M, Elliott D, Wade J, Avery K, et al.
Optimising recruitment and informed consent in randomised controlled
trials: the development and implementation of the quintet recruitment
intervention (QRI). Trials. 2016;17:1–11. Available from. https://doi.org/10.
1186/s13063-016-1391-4.
11. Antoniou SA, Andreou A, Antoniou GA, Koch OO, Köhler G, Luketina RR,
et al. Volume and methodological quality of randomized controlled trials in
laparoscopic surgery: assessment over a 10-year period. Am J Surg. 2015;
210:922–9.
12. Ali UA, van der Sluis PC, Issa Y, Habaga IA, Gooszen HG, Flum DR, et al.
Trends in worldwide volume and methodological quality of surgical
randomized controlled trials. Ann Surg. 2013;258:199–207.
13. Kristensen N, Nymann C, Konradsen H. Implementing research results in
clinical practice - the experiences of healthcare professionals. BMC Health
Serv Res. 2016;16:48. Available from. https://doi.org/10.1186/s12913-016-
1292-y.
14. Blencowe NS, Boddy AP, Harris A, Hanna T, Whiting P, Cook JA, et al.
Systematic review of intervention design and delivery in pragmatic and
explanatory surgical randomized clinical trials. Br J Surg. 2015;102:1037–47.
15. Rothwell PM. External validity of randomised controlled trials: “to whom do
the results of this trial apply?”. Lancet. 2005;365:82–93.
16. Orri M, Farges O, Clavien P-A, Barkun J, Revah-Lévy A. Being a surgeon - the
myth and the reality. A meta-synthesis of surgeons’ perspectives about
factors affecting their practice and well-being. Ann Surg. 2014;260:721–9
Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:
landingpage&an=00000658-201411000-00002.
17. Garcia-Retamero R, Cokely ET, Wicki B, Joeris A. Improving risk literacy in
surgeons. Patient Educ Couns. 2016;99:1156–61. Available from. https://doi.
org/10.1016/j.pec.2016.01.013.
18. Byrne BE, Rooshenas L, Lambert H, Blazeby JM. Evidence into practice:
protocol for a new mixed-methods approach to explore the relationship
between trials evidence and clinical practice through systematic
identification and analysis of articles citing randomised controlled trials. BMJ
Open. 2018;8:e023215 Available from: http://bmjopen.bmj.com/lookup/doi/1
0.1136/bmjopen-2018-023215.
19. Biere SSAY, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C,
Garcia JR, et al. Minimally invasive versus open oesophagectomy for
patients with oesophageal cancer: a multicentre, open-label, randomised
controlled trial. Lancet. 2012;379:1887–92.
20. Yin RK. Case study research and applications: design and methods. Sixth:
SAGE Publications; 2018.
21. Crowe S, Cresswell K, Robertson A, Huby G, Avery A, Sheikh A. The case
study approach. BMC Med Res Methodol. 2011;11:100.
22. Stake RE. The art of case study research. Thousand Oaks: SAGE Publications;
1995.
23. Glaser BG, Strauss AL. The discovery of grounded theory: strategies for
qualitative research. Observations. Aldine Transaction; 1967. Available from:
http://www.amazon.com/dp/0202302601.
24. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol.
2006;3:77–101 [cited 2014 May 25]. Available from: http://www.tandfonline.
com/doi/abs/10.1191/1478088706qp063oa.
25. Pfadenhauer L, Rohwer A, Burns J, Booth A, Lysdahl KB, Hofmann B, et al.
Guidance for the assessment of context and implementation in Health
Technology Assessments (HTA) and systematic reviews of complex
interventions: the Context and Implementation of Complex Interventions




26. Biere SSAY, Maas KW, Bonavina L, Garcia JR, van Berge Henegouwen MI,
Rosman C, et al. Traditional invasive vs. minimally invasive esophagectomy:






27. Fitzgerald L, Ferlie E, Wood M, Hawkins C. Interlocking interactions, the
diffusion of innovations in health care. Hum Relat. 2002;55:1429–49.
28. Fitzgerald L, Ferlie E, Wood M, Hawkins C. Evidence into practice? An
exploratory analysis of the interpretation of evidence. In: Mark AL, Dopson S,
editors. Organisational Behaviour in Health Care: The Research Agenda.
Palgrave Macmillan; 1999.
29. Latour B. Reassembling the social: an introduction to actor-network theory.
Oxford: Oxford University Press; 2005..
30. Cresswell KM, Worth A, Sheikh A. Actor-network theory and its role in
understanding the implementation of information technology
developments in healthcare. BMC Med Inform Decis Mak. 2010;10:1–11.
31. Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375:454–63.
32. Luketich JD, Pennathur A, Awais O, Levy RM, Keeley R, Shende M, et al.
Outcomes after minimally invasive esophagectomy: review of over 1000
patients. Ann Surg. 2012;256:95–103.
33. Birkmeyer JD, Finks JF, O’Reilly A, Oerline M, Carlin AM, Nunn AR, et al.
Surgical skill and complication rates after bariatric surgery. N Engl J Med.
2013;369:1434–42 [cited 2014 Jul 23]. Available from: http://www.ncbi.nlm.
nih.gov/pubmed/24106936.
34. Ebrahim S, Ferrie JE, Smith GD. The future of epidemiology: methods or
matter? Int J Epidemiol. 2016;45:1699–716.
35. Jackson SE, Chester JD. Personalised cancer medicine. Int J Cancer. 2015;
137:262–6.
36. Backmann M. What’s in a gold standard? In defence of randomised
controlled trials. Med Health Care Philos. 2017;20:513–23.
37. Evidence-based Medicine Working Group. Evidence-based medicine: a new
approach to teaching the practice of medicine. J Am Med Assoc. 1992;268:
2420–5 Available from: http://content.wkhealth.com/linkback/openurl?sid=
WKPTLP:landingpage&an=00006534-201412000-00040.
38. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of
treatment effects, and the trouble with averages. Milbank Q. 2004;82:661–
87.
39. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC.
Fostering implementation of health services research findings into practice:
a consolidated framework for advancing implementation science.
Implement Sci. 2009;4:50.
40. Urbach DR, Baxter NN. Reducing variation in surgical care. Br Med J. 2005;
330:1401–2.
41. Gramlich LM, Sheppard CE, Wasylak T, Gilmour LE, Ljungqvist O, Basualdo-
Hammond C, et al. Implementation of Enhanced Recovery After Surgery: a
strategy to transform surgical care across a health system. Implement Sci.
2017;12:67.
42. Michie S, Johnston M, Abraham C, Lawton R, Parker D, Walker A. Making
psychological theory useful for implementing evidence based practice: a
consensus approach. Qual Saf Heal Care. 2005;14:26–33.
43. Cane J, O’Connor D, Michie S. Validation of the theoretical domains
framework for use in behaviour change and implementation research.
Implement Sci. 2012;7:1–17.
44. Ritchie J, Spencer L. In: Bryman A, Burgess RG, editors. Qualitative data
analysis for applied policy research. Routledge: Anal Qual data; 1994.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Byrne et al. BMC Medical Research Methodology          (2020) 20:112 Page 12 of 12
